个体化放射性栓塞改善难治性肝内胆管癌预后:多中心研究
这项回顾性多中心研究纳入58例不可切除且化疗难治的肝内胆管癌患者,均接受树脂90Y微球放射性栓塞治疗。中位总生存期为10.3个月,按体表面积(BSA)处方活度的患者中位总生存期显著短于按分区模型个体化处方的患者(5.5 vs 14.9个月)。多因素分析显示,活度处方方法是唯一在临床变量之上额外改善预后预测的变量。
要点
- 个体化分区模型处方活度的中位总生存期优于BSA法(14.9 vs 5.5个月)。
- 肿瘤平均辐射剂量在分区模型组显著高于BSA组(86Gy vs 38Gy)。
- 淋巴结转移及TLRMAA<1.9与更短的中位总生存期相关。
核心结论
- 不可切除复发和/或化疗难治性肝内胆管癌的放射性栓塞疗效在很大程度上取决于肿瘤辐射剂量。
- 应进行个体化活度处方。
研究设计与样本
- 回顾性多中心研究纳入58例不可切除且化疗难治的肝内胆管癌患者,均接受树脂90Y微球放射性栓塞治疗。
主要发现
- 整个队列放射性栓塞后中位总生存期为10.3个月。
- 按BSA法治疗的患者中位总生存期显著短于按分区模型治疗的患者:5.5 vs 14.9个月(HR=2.52,95%CI:1.23-5.16,p<0.001)。
- 多因素分析显示,活度处方方法是唯一在临床变量之上增加预后预测的变量,HR为2.26(95%CI:1.09-4.70,p=0.03)。
- 肿瘤平均辐射剂量在分区模型组显著高于BSA组(86Gy vs 38Gy)。
关键数值与推荐
- 血清白蛋白与总生存期显著相关(HR=2.78,95%CI:1.29-5.98,p=0.002)。
- 总胆红素与总生存期显著相关(HR=2.17,95%CI:1.14-4.12,p=0.009)。
- 天冬氨酸氨基转移酶与总生存期显著相关(HR=2.96,95%CI:1.50-5.84,p<0.001)。
- 丙氨酸氨基转移酶与总生存期显著相关(HR=2.02,95%CI:1.05-3.90,p=0.01)。
- γ-谷氨酰转移酶与总生存期显著相关(HR=2.61,95%CI:1.31-5.22,p<0.001)。
临床怎么用
- 对不可切除复发和/或化疗难治性肝内胆管癌患者行放射性栓塞时,应优先采用基于分区模型的个体化活度处方,而非BSA法。
- 治疗前应评估血清白蛋白、总胆红素、转氨酶、γ-GT、淋巴结转移及TLRMAA等预后相关变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reported outcomes of patients with intra-hepatic cholangiocarcinoma (IH-CCA) treated with radioembolization are highly variable, which indicates differences in included patients' characteristics and/or procedure-related variables. This study aimed to identify patient- and treatment-related variables predictive for radioembolization outcome. METHODS: This retrospective multicenter study enrolled 58 patients with unresectable and chemorefractory IH-CCA treated with resin 90Y-microspheres. Clinicopathologic data were collected from patient records. Metabolic parameters of liver tumor(s) and presence of lymph node metastasis were measured on baseline 18F-FDG-PET/CT. 99mTc-MAA tumor to liver uptake ratio (TLRMAA) was computed for each lesion on the SPECT-CT. Activity prescription using body-surface-area (BSA) or more personalized partition-model was recorded. The study endpoint was overall survival (OS) starting from date of radioembolization. Statistical analysis was performed by the log-rank test and multivariate Cox's proportional hazards model. RESULTS: Median OS (mOS) post-radioembolization of the entire cohort was 10.3 months. Variables associated with significant differences in terms of OS were serum albumin (hazard ratio (HR) = 2.78, 95%CI:1.29-5.98, p = 0.002), total bilirubin (HR = 2.17, 95%CI:1.14-4.12, p = 0.009), aspartate aminotransferase (HR = 2.96, 95%CI:1.50-5.84, p < 0.001), alanine aminotransferase (HR = 2.02, 95%CI:1.05-3.90, p = 0.01) and γ-GT (HR = 2.61, 95%CI:1.31-5.22, p < 0.001). The presence of lymph node metastasis as well as a TLRMAA < 1.9 were associated with shorter mOS: HR = 2.35, 95%CI:1.08-5.11, p = 0.008 and HR = 2.92, 95%CI:1.01-8.44, p = 0.009, respectively. Finally, mOS was significantly shorter in patients treated according to the BSA method compared to the partition-model: mOS of 5.5 vs 14.9 months (HR = 2.52, 95%CI:1.23-5.16, p < 0.001). Multivariate analysis indicated that the only variable that increased outcome prediction above the clinical variables was the activity prescription method with HR of 2.26 (95%CI:1.09-4.70, p = 0.03). The average mean radiation dose to tumors was significantly higher with the partition-model (86Gy) versus BSA (38Gy). CONCLUSION: Radioembolization efficacy in patients with unresectable recurrent and/or chemorefractory IH-CCA strongly depends on the tumor radiation dose. Personalized activity prescription should be performed.
引用
- Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019. PMID: 31324943. doi:10.1007/s00259-019-04427-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。